pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiska medel - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
bortezomib baxter 3,5 mg pulver till injektionsvätska, lösning
baxter holding b.v. - bortezomib - pulver till injektionsvätska, lösning - 3,5 mg - bortezomib 3,5 mg aktiv substans; mannitol hjälpämne
metoclopramide baxter 5 mg/ml injektionsvätska, lösning
baxter holding b.v. - metoklopramidhydrokloridmonohydrat - injektionsvätska, lösning - 5 mg/ml - metoklopramidhydrokloridmonohydrat 5,27 mg aktiv substans
tranexamic acid baxter 100 mg/ml injektions-/infusionsvätska, lösning
baxter holding b.v. - tranexamsyra - injektions-/infusionsvätska, lösning - 100 mg/ml - tranexamsyra 100 mg aktiv substans
dexmedetomidine baxter 100 mikrogram/ml koncentrat till infusionsvätska, lösning
baxter holding b.v. - dexmedetomidinhydroklorid - koncentrat till infusionsvätska, lösning - 100 mikrogram/ml - dexmedetomidinhydroklorid 118 mikrog aktiv substans
paracetamol baxter 10 mg/ml infusionsvätska, lösning
baxter holding b.v. - paracetamol - infusionsvätska, lösning - 10 mg/ml - mannitol hjälpämne; paracetamol 10 mg aktiv substans
paracetamol baxter viaflo 10 mg/ml infusionsvätska, lösning
baxter holding b.v. - paracetamol - infusionsvätska, lösning - 10 mg/ml - mannitol hjälpämne; paracetamol 10 mg aktiv substans
bupivacaine baxter 2,5 mg/ml injektionsvätska, lösning
baxter holding b.v. - bupivakainhydroklorid, vattenfri - injektionsvätska, lösning - 2,5 mg/ml - bupivakainhydroklorid, vattenfri 2,5 mg aktiv substans
bupivacaine baxter 5 mg/ml injektionsvätska, lösning
baxter holding b.v. - bupivakainhydroklorid, vattenfri - injektionsvätska, lösning - 5 mg/ml - bupivakainhydroklorid, vattenfri 5 mg aktiv substans
sugammadex baxter 100 mg/ml injektionsvätska, lösning
baxter holding b.v. - sugammadexnatrium - injektionsvätska, lösning - 100 mg/ml - sugammadexnatrium 108,8 mg aktiv substans